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neovascularization, and a lack of endothelial regeneration. 2 Thus, there is a great need for therapeutic interventions aimed at accelerating repair of dysfunctional endothelium and restoring blood flow in diabetic patients.
Accumulating evidence suggests that bone marrowderived circulating endothelial progenitor cells (EPCs) contribute to vascular repair. After tissue ischemia or endothelial damage, EPCs are mobilized from the bone marrow to the circulation. EPCs then home to sites of vascular injury where they contribute to new blood vessel formation and recovery. 3 Recently, EPC transplantation has become an experimental therapy for ischemic disease. 4 Several studies show that EPC transplantation provides some benefit for myocardial infarction 5 and limb ischemia, 6, 7 and transplanted EPCs may compensate for a shortage of endogenous EPCs in diabetic retinopathy. 8 However, to improve therapeutic efficacy of EPC transplantation, it is necessary to improve EPC survival and enhance EPC homing to ischemic tissue.
EPC-induced neovascularization is a highly coordinated, temporally regulated, and complex set of events including mobilization, migration, and homing. 9, 10 Chemokines play an essential role in each of these steps. Stromal cell-derived factor 1 (SDF-1, also known as CXCL12) is a key chemokine in regulating hematopoietic stem cell trafficking between the bone marrow and peripheral circulation and attracts EPCs to areas of ischemia. For some time, chemokine receptor type 4 (CXCR4) was thought to be the only SDF-1 receptor, and numerous studies demonstrated a role of the SDF-1/CXCR4 axis in mobilizing stem and progenitor cells from bone marrow, homing to target tissue, chemotaxis, adhesion, survival, and angiogenesis. 11, 12 In 2005, a second SDF-1 receptor was identified, CXCR7 that binds SDF-1 with 10-fold higher affinity than CXCR4. 13 EPCs express both CXCR4 and CXCR7 14, 15 and recently CXCR7 is shown to influence EPCs clinical status, that is, EPCs of hypertensive patients express low levels of CXCR7 and this contributes to impaired angiogenesis and re-endothelialization. 16 In diabetes mellitus, the number of EPCs is reduced and EPC function is attenuated. 17 Diabetes mellitus may alter expression and function of SDF-1 receptors in EPCs, but this remains untested. Our previous studies demonstrated that CXCR7 has a critical role regulating adhesion and survival of EPCs from rat bone marrow and human cord blood. 14, 15 Extrapolating from those studies, we hypothesized that elevating CXCR7 expression would improve angiogenic function of EPCs in type 2 diabetes mellitus. The aims of the present study were to determine the level of SDF-1 receptors in diabetic EPCs and determine whether overexpression of CXCR7 improved angiogenic function of EPCs in diabetes mellitus and to reveal mechanisms connecting EPC function and CXCR7 expression.
Methods

Animals
FVB wild-type (WT) and db/db (FVB background) male mice of 10 to 12 weeks were used in this study. All animal procedures were approved by the Animal Policy and Welfare Committee of Wenzhou Medical
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Novelty and Significance
What Is Known?
• Diabetes mellitus associated dysregulation of endothelial regeneration may attribute to the dysfunction of endothelial progenitor cells (EPCs).
• CXC chemokine receptor 7 (CXCR7) plays a critical role in EPC angiogenic function. Diabetes mellitus may alter expression and function of CXCR7 in EPCs but this remains untested.
What New Information Does This Article Contribute?
• CXCR7 is necessary for diabetic EPCs survival, resistance to oxidative stress, and angiogenic capacity.
• The benefits of CXCR7 in EPCs under diabetic conditions require activation of nuclear factor (erythroid-derived 2)-like 2 antioxidant signaling.
• The protein kinase B/glycogen synthase kinase 3β/tyrosine kinase Fyn pathway mediates CXCR7-induced nuclear factor (erythroid-derived 2)-like 2 activation in EPCs under diabetic conditions.
EPCs respond to stromal cell-derived factor 1 through receptors CXCR7 and CXCR4. 
Isolation and Culture of Bone Marrow-Derived EPC
EPCs were isolated from the bone marrow of WT (WT-EPCs) and db/db (db/db-EPCs) mice and cultured afterward according to our established methods with minor modifications. 15 Briefly, bone marrow mononuclear cells (MNCs) were isolated from the femurs and tibias of mice by density gradient centrifugation with histopaque-1083 (Sigma-Aldrich, St. Louis, MO). After 2 washing steps, MNCs were plated on vitronectin-coated culture dishes (Sigma-Aldrich) and maintained in endothelial growth factor-supplemented media (EGM-2 bullet kit; Lonza, Basel, Switzerland) with 10% FBS. Cells were cultured at 37°C with 5% CO 2 in a humidified atmosphere. EGM-2 medium was replaced after the first 24 hours and every 3 days thereafter. Cell colonies that appeared after 7 days of culture were defined as early EPC, and cell colonies that appeared after 14 days of culture were defined as late EPC as previous reported.
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Characterization of Bone Marrow-Derived MNCs
After 7 or 14 days in endothelial-specific media and the removal of nonadherent MNCs, the remaining cells were characterized by immunofluorescent staining and flow cytometry analysis. For immunofluorescent staining, cells were seeded on vitronectin-coated 8-well μ-slide (ibidi, Martinsried, Germany) 1 day before and then the cells were incubated with 5 μg/mL acetylated DiI lipoprotein from human plasma (Dil-Ac-LDL; Thermo Fisher Scientific, Waltham, MA) at 37°C for 4 hours followed by 3 washes with Dulbecco PBS (DPBS) and incubated with 10 μg/mL fluorescein isothiocyanatelabeled ulex europaeus lectin-1 (Sigma-Aldrich) for 1 hour at room temperature. After incubation, cells were rinsed with DPBS for 3× and were visualized via a confocal microscopy. For flow cytometry analysis, cells were incubated with 5% BSA (Sigma) for 15 minutes for blockade of nonspecific binding and then stained with antimouse CD34-phycoerythrin (PE), CD31-PE, CD14-PE, CD144-PE, Scal-1-fluorescein isothiocyanate, c-kit-fluorescein isothiocyanate (BD Biosciences, San Jose, CA), and VEGFR2-APC (vascular endothelial growth factor receptor 2-allophycocyanin), CD45-APC (Biolegend, San Diego, CA) at room temperature for 1 hour, respectively. The same fluorescein-labeled isotype IgG served as control to define the negative populations for each stain. Cells were analyzed with a BD FACSAria cell sorter (BD Biosciences), and data were analyzed using FloJo software version 8.8.4 (TreeStar, Inc, Ashland, OR).
Lentiviral Vector Construction, Virus Production, and Infection
To upregulate the CXCR7 expression in EPCs, recombinant lentiviruses encoding CXCR7 (pLVX-CXCR7-EGFP-3FLAG-Puro) was constructed by cloning the CXCR7 gene into the pLVX-EGFP-3FLAG-Puro vector (Shanghai Sunbio Medical Biotechnology, Shanghai, China) via EcoRI and BamHI sites. The CXCR7 cDNA was amplified using the following primers: forward: 5′-CGGAATTCCGCCTCAGAACGATGGATC-3′ reverse: 5′-CGGGAGCCAACAAGTAAACCCGTCCCAGA-3′.
Viral supernatants were produced in human embryonic kidney 293 cells constitutively expressing the simian virus 40 (SV40) large T antigen after cotransfection of CXCR7 recombinant vector (pLVX-CXCR7-EGFP-3FLAG-Puro) or control vector (pLVX-EGFP-3FLAG-Puro) with the packaging plasmid psPAX2 and the envelope plasmid pMD2.G using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The supernatant was harvested at 72 hours post-transfection, filtered through Millex-HV 0.45-μm polyvinylidene fluoride filter (Millipore, Billerica, MA), and stored at −80°C until use.
Early EPCs or late EPCs (passages 3-4) were infected with the purified lentivirus carrying recombinant CXCR7 (CXCR7-EPCs) or control vector (Null-EPCs) overnight at multiplicity of infection of 25 with 2.5 μg/mL polybrene (Santa Cruz, Dallas, TX), and the medium was replaced with fresh growth medium 24 hours after infection. After transfection for 72 hours, the infection efficiency was determined by flow cytometry analysis of green fluorescent protein (GFP) expression. The levels of CXCR7 expression were detected by Western blot and flow cytometry assay.
To knockdown CXCR7 expression in early EPCs from WT mice, specific siRNAs against mouse CXCR7, alone with Silencer Select Negative Control (Thermo Fisher) were transfected into EPCs using Lipofectamine 2000 (Thermo Fisher). After transfection for 48 hours, the expression of CXCR7 was determined by Western blot.
To knockdown nuclear factor (erythroid-derived 2)-like 2 (Nrf2) expression in late EPCs from WT mice, EPCs were infected with the lentiviruses containing shRNA against Nrf2 or nonsense shRNA constructed by Shanghai Sunbio Medical Biotechnology (Shanghai, China). We selected 3 target sequences for Nrf2 and nonsense sequence as follows:
Nrf2-shRNA 1:5′-CTTGAAGTCTTCAGCATGTTA-3′; Nrf2-shRNA 2: 5′-GCCTTACTCTCCCAGTGAATA-3′; Nrf2-shRNA 3: 5′-GACCTCCTTAGACTAAATCC-3′. Nonsense shRNA: 5′-TTCTCCGAACGTGTCACGTTT-3′.
The transfection was performed after the procedure described above. After transfection for 48 hours, the expression of Nrf2 was determined by Western blot. Then CXCR7-EPCs or Null-EPCs were infected with the lentiviruses containing shRNA against Nrf2 with the best knockdown efficiency or nonsense shRNA after the same protocol described above.
Apoptosis Assay
EPCs transduced with control lentivirus or lentivirus encoding CXCR7, Nrf2 shRNA, or nontarget shRNA were seeded on 12-well plates ( 
Angiogenesis Assay In Vitro
The in vitro angiogenic capability of EPCs was determined by matrigel tube formation assay. Briefly, 48-well plates were coated with growth factor-reduced matrixgel (150 μL/well; BD Biosciences). EPCs transduced with control lentivirus or lentivirus encoding CXCR7, Nrf2 shRNA, or nontarget shRNA were plated (5×10 4 cells per well) in 200-μL basal culture medium or medium containing ox-LDL or HG in the presence or absence of SDF-1 and incubated at 37°C with 5% CO 2 for 12 hours to form tubes. Images of tubes in each well were taken using an inverted microscopy (Nikon Eclipse E600; Nikon, Kanagawa, Japan). The tube lengths were calculated by Image J software.
Transendothelial Migration Assay
Transendothelial migration (TEM) is one of most important abilities for EPCs participating in angiogenesis. We evaluated TEM abilities of EPCs by a transwell assay according to our previous report. 15 Human umbilical vein endothelial cells (1×10 4 cells per well) were cultured in the upper chamber of a 24-transwell insert (8.0-μm pores; Falcon 353097; BD, Bedford, MA). Before each experiment, monolayer confluency was confirmed by inverted fluorescence microscopy. EPCs transduced with control lentivirus or lentivirus encoding CXCR7, Nrf2 shRNA, or nontarget shRNA were cultured in the presence or absence of ox-LDL for 12 hours or HG for 24 hours. Then EPCs were harvested and resuspended in basal culture medium (EBM-2, 0.5% BSA). EPC suspension (0.2 mL) was added to the upper chamber of the transwell, and 0.6 mL EBM-2 medium supplemented with either PBS or SDF-1 (100 ng/mL) was added to the lower chamber of the transwell. Cells were cultured for 12 hours at 37°C, and EPCs traversing from the upper to the lower chamber of the transwell was quantified by independent investigators blinded to treatment.
Quantitative Determination of Oxidative Stress
To detect the reactive oxygen species (ROS) level of EPCs with ox-LDL or HG treatment, dihydroethidium (Molecular Probes, Eugene, OR) probe was used to stain EPCs. Dihydroethidium is cell permeable and able to react with superoxide to form ethidium, which in turn intercalates with DNA and produces nuclear fluorescence. EPCs were seeded on 24-well plates and treated with ox-LDL or HG in presence or absence SDF-1 for 6 hours and then incubated with 5 μmol/L dihydroethidium in PBS for 30 minutes at 37°C. Nuclear dihydroethidium positive staining indicates superoxide generation in cells. The fluorescence intensity was detected by a microplate reader (SpectraMax M3; Molecular Devices, Sunnyvale, CA) under specific wavelength conditions (excitation, 518 nm; fluorescence, 605 nm). Meanwhile, the fluorescence images of random EPCs were captured at ×20 magnification (XI 71 Olympus, Tokyo, Japan).
Western Blot Assay
Western blot was performed as previous study. 15 For cellular protein extraction, EPCs were rinsed twice with PBS and then suspended in ice-cold RIPA lysis buffer (Santa Cruz Biotechnology, Dallas, TX) and incubated for 15 to 30 minutes on ice. Nuclear proteins from EPCs were extracted by a nuclear extraction kit (Abcam, Cambridge, MA). Proteins were collected by centrifugation, 12 000g for 15 minutes at 4°C. The protein concentration was determined using a Bradford protein assay kit (Bio-Rad, Hercules, CA). The total and nuclear proteins were separated on 10% SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked in tris-buffered saline with 5% nonfat milk and 0.5% BSA for 1 hour and then incubated with the primary antibody overnight at 4°C, followed by incubation with the secondary antibodies for 1 hour at room temperature after standard washing procedures. The primary antibodies against Nrf2 (1:1000), histone H3 (1:1000), heme oxygenase-1 (HO-1, 1:2000), NAD(P)H dehydrogenase quinone 1 (NQO-1, 1:1000), catalase (1:5000), GAPDH (1:5000), and β-actin (1:3000) were purchased from Santa Cruz Biotechnology; protein kinase B (Akt) and p-Akt (Ser473; 1:2000), glycogen synthase kinase (GSK)-3β and p-GSK-3β (Ser9) (1:2000) , and Fyn (1:2000) were purchased from Cell Signaling Technology (Danvers, MA); 3-nitrotyrosine (1:2000) was purchased from Millipore (Billerica, MA); CXCR4 and CXCR7 (1:2000) were purchased from Abcam. All horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology. Blots were visualized with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) and quantified with Quantity 5.2 software System (Bio-Rad).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted using Trizol reagent (RNA STAT 60; TelTest Inc., Austin, TX) and reversed transcribed using a GoScript Reverse Transcription System (Promega, Madison, WI) following the manufacturer's protocol. Primers of Nrf2 (Mm00477784), catalase (Mm00437992_m1), NQO-1 (Mm01253561), HO-1 (Mm00516005), and β-actin (Mm00607939) were purchased from Thermo Fisher Scientific. Quantitative real-time polymerase chain reaction was performed in duplicate with a 20-μL reaction system, which contains 10-μL TaqMan Universal polymerase chain reaction master mix, 6-μL H 2 O, 3-μL cDNA, and 1-μL primer, using the ABI 7500 real-time polymerase chain reaction system (Applied Biosystems, Foster City, CA). The comparative cycle time (Ct) method was used to determine fold differences between samples, and the amount of target genes was normalized to β-actin as an endogenous reference (2 −∆∆Ct ).
Hindlimb Ischemia Model and Cell Therapy
The db/+ founder mice (FVB.BKS(D)-Lepr db/+ /ChuaJ, FVB background) were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained under specific pathogen-free conditions at the University of Louisville Animal Facility (Louisville, KY). The db/ db mice were generated by breeding male db/+ to female db/+ mice following Jackson Laboratory's instructions. Male db/db mice were used to develop hindlimb ischemia (HLI) model as in our previous report. 19 Briefly, under sufficient anesthesia with isoflurane (1%-3% isoflurane in 100% oxygen at a flowrate of 1 L/min), the hind limbs were shaved and the entire right superficial femoral artery and vein (from just below of deep femoral arteries to popliteal artery and vein) were ligated with 6-0 silk sutures, cut, and excised with an electric coagulator (Fine Science Tools Inc., Foster City, CA). The overlying skin was closed with 4-0 silk sutures.
After surgery, 1×10 6 EPCs, infected with lentivirus vector, lentivirus carrying CXCR7, shRNA against Nrf2 or nonspecific shRNA sequence, were infused via tail vein. To evaluate limb perfusion ratio (ischemic limb [right]/normal limb [left]), real-time microcirculation imaging analysis was performed using a Pericam Perfusion Speckle Imager based on the laser speckle contrast analysis technology (Perimed Inc., Kings Park, NY) at days 0, 3, 7 14, 21, and 28 post-ischemia.
Histological Assessment
To examine the homing and incorporation of EPCs in the ischemic muscle, ischemic gastrocnemius muscle and soleus muscle were embedded in optimal cutting temperature medium for frozen section. The GFP-positive EPCs were counted in randomly selected fields for a total of 20 different fields (×40 magnification) per section and 3 sections per animal. The EPC incorporation was expressed as the percentage of GFP-positive capillaries.
The extent of angiogenesis and arteriogenesis at day 28 postischemic surgery was assessed by measuring capillary density in gastrocnemius muscle and soleus muscle using isolectin B4 staining and arteriole area in adductor muscle. Ischemic gastrocnemius muscle, soleus muscle, and adductor tissues were fixed with 4% paraformaldehyde and embedded with paraffin. Paraffin sections were cut at 5 μm and stained with Alexa Fluor 594 conjugated isolectin GS-IB4 (Thermo Scientific) or anti-α-smooth muscle actin antibody (Abcam) to evaluate the capillary density and arteriole area, respectively. The number of capillaries or arteriole area were calculated in randomly selected fields for a total of 20 different fields (×40 magnification) per section and 3 sections per animal. The capillary density was expressed as capillary number per muscle fiber, and the arteriole area was expressed as α-smooth muscle actin-positive arteriole area per fiber and normalized by control.
Statistical Analysis
All data are presented as mean±SD. Statistical analysis was performed using Origin 7.5 (OriginLab data analysis and graphing software) with 1-way or 2-way ANOVA, followed by post hoc multiple comparisons with the Scheffe test. Statistical significance was considered as P<0.05.
Results
Characterization of Bone Marrow-Derived EPCs
MNCs isolated from mouse bone marrow were cultured in EGM-2 medium on vitronectin-coated culture dishes. Three days after plating cell colonies appeared with centrally rounded cells and spindly peripheral cells (Online Figure IA, left) . By 7 days, spindle-shaped adherent early EPCs were observed (Online Figure IA, middle) . By 14 to 21 days of culture, endothelium-like cells with cobblestone-like morphology late EPCs were nearly confluent (Online Figure IA, right) . Both early and late EPCs are positive for DiI-acLDL and UEA-1 stains (Online Figure IB and IC) . Flow cytometry demonstrated that many early EPCs were positive for CD34, CD31, CD14, CD45, Scal-1, c-Kit, and VEGFR2, but mostly negative for CD144 (Online Figure ID with quantitation) . The cell surface profile of late EPCs was positive for CD34, CD31, VEGFR2, CD144, c-Kit, and Scal-1, but low or negative for both CD14 and CD45 (Online Figure IE with quantitation) . These characteristics were consistent with previous of descriptions EPCs. 18, 20, 21 
Diabetes Mellitus Attenuates CXCR7 Expression and Impairs Angiogenic Function of EPCs
To determine how EPCs were affected by prolonged in vivo diabetes mellitus, early EPCs were isolated from bone marrow of WT and db/db mice and assayed for expression of SDF-1 receptors and for tube formation. Total and cell surface expression of CXCR7 were significantly decreased in EPCs from db/db mice compared with those from WT mice, whereas no significant differences were seen for CXCR4 expression ( Figure 1A and 1B) . Tube formation by EPCs from db/db mice was also functionally deficient as indicated by the significantly shorter length of the tubes db/db EPCs produced compared with WT-EPCs ( Figure 1C) .
To determine whether reduced CXCR7 expression in diabetic EPCs was a cause of angiogenic dysfunction, gain-and loss-of-function studies were performed by CXCR7-siRNA knockdown in early EPCs from WT mice, and CXCR7 overexpression with CXCR7 lentivirus in early EPCs from db/ db mice. CXCR7 levels were significantly reduced by the siRNA in WT-EPCs (Online Figure II) , and this was accompanied by impaired tube formation ( Figure 1D ). Conversely, increasing CXCR7 levels in db/db EPCs with CXCR7 lentivirus (Online Figure II) completely reversed impaired tube formation function of diabetic EPCs ( Figure 1D ). Most importantly, transplantation of CXCR7 recombinant lentiviral vector transfected db/db EPCs time dependently improved blood perfusion in HLI in db/db mice (Figure 2A ), which was accompanied by promoted angiogenesis mirrored by increased capillary density and exogenous EPCs incorporation mirrored by GFP encoded by the transduced lentivirus vector and isolectin colocalization in both soleus muscle ( Figure 2B ) and gastrocnemius muscle ( Figure 2C ) measured 28 days after HLI, but without obvious effects on arteriogenesis mirrored by no apparent changes in α-smooth muscle actin-positive arteriole area in adductor muscle ( Figure 2D ). These results suggest that diabetic downregulation of CXCR7 plays a causative role in diabetes mellitus-induced EPCs angiogenic dysfunction.
Upregulating CXCR7 Expression Improves Survival and Angiogenic Function of EPCs Treated With ox-LDL and HG
To overcome the shortage of number of limitation of early EPCs and facilitate gene manipulation, late EPCs from WT mice were used for the following mechanistic studies. Late EPCs from WT mice were transduced with CXCR7 recombinant lentiviral vector or control vector. At 72 hours after transduction, transfection efficiency was >70% as measured by GFP expression (Online Figure IIIA) . CXCR7 expression was dramatically increased in CXCR7-EPCs compared with NullEPCs and WT-EPCs as determined by flow cytometry (Online Figure IIIB) and Western blot assay (Online Figure IIIC) .
To determine whether the effects of diabetes mellitus could be reproduced in vitro, late EPCs from WT mice were treated with ox-LDL or HG to mimic conditions of diabetic dyslipidemia or hyperglycemia as previous report. 22 As found with db/db diabetes, both ox-LDL and HG dose dependently decreased the expression of CXCR7 but not that of CXCR4, except at a highest dose of HG (Online Figure IVA and IVC) . Ox-LDL and HG also impaired tube formation by EPCs from WT mice (Online Figure IVB and IVD) . These results show that both ox-LDL and HG treatment can recapture the effects of diabetes mellitus on CXCR7 expression and EPCs dysfunction.
To test the effects of CXCR7 manipulation on EPC function in vitro, EPC dysfunction was induced by 24-hour exposure late EPCs from WT mice to ox-LDL at 50 μg/mL or HG at 25 mmol/L, chosen on the basis of the dose-response study in Online Figure IV . Apoptosis, measured with Annexin V/ propidium iodide staining ( Figure 3A ; Online Figure VA ) was greatly increased in Null-EPCs by both ox-LDL and HG. This was slightly but not significantly reduced by SDF-1 pretreatment. In CXCR7-EPCs, both ox-LDL and HG also induced apoptosis, but it was significantly less than in Null-EPCs. Most striking was the almost complete protection against apoptosis in CXCR7-EPCs by SDF-1 pretreatment.
Tube formation assays were used as one measure of in vitro angiogenic function ( Figure 3B ; Online Figure VB) . Both Ox-LDL and HG significantly impaired the tube formation abilities in Null-EPCs. As with apoptosis, the negative effect on tube formation was slightly but not significantly reduced by SDF-1 pretreatment in Null-EPCs. In CXCR7-EPCs, ox-LDL and HG had less inhibitory effect on tube formation and SDF-1 pretreatment provided much more effective protection against ox-LDL and HG inhibition than it did in Null-EPCs.
TEM is essential for EPC homing to the sites of blood vessel repair and formation and was assayed by transwell migration assay ( Figure 3C ; Online Figure VC) . The assay showed no significant difference in basal TEM between Null-EPCs and CXCR7-EPC. When EPCs were treated with SDF-1, TEM of CXCR7-EPCs was much higher than that of Null-EPCs. Ox-LDL and HG pretreatment almost completely abolished SDF-1-stimulated increase of TEM in Null-EPCs, but in CXCR7-EPCs, the ability of SDF-1 to increase TEM was significantly preserved.
Upregulating CXCR7 Expression Promotes EPCsMediated Angiogenesis and Blood Perfusion in HLI in db/db Type 2 Diabetes Mellitus
To determine whether elevated CXCR7 improves late EPCmediated neovascularization in type 2 diabetes mellitus in vivo, we transplanted CXCR7-EPCs or Null-EPCs into db/db mice after HLI surgery. Both Null-EPCs and CXCR7-EPCs transplantation time dependently increased blood perfusion compared with mice without transplantation. Notably, CXCR7-EPCs were significantly more effective than NullEPCs at all time points from days 7 to 28 (Online Figure VIA) . The benefit of CXCR7-EPCs was also apparent in increased capillary density and exogenous EPCs incorporation measured 28 days after HLI (Online Figure VIB) . These findings indicate that CXCR7 overexpression also promotes late EPCs homing and incorporating in endothelium in the ischemic tissue.
Upregulating CXCR7 Expression Attenuates ox-LDL-and HG-Induced Oxidative Stress in EPCs
Oxidative stress is a major factor responsible for the dysfunction of diabetic EPCs. 23, 24 Here, we show that ROS levels and oxidative damage produced by ox-LDL and HG are significantly reduced by elevated expression of CXCR7. Both ox-LDL and HG induced superoxide production in Null-EPCs, as measured by dihydroethidium staining, and superoxide was slightly reduced by SDF-1 pretreatment ( Figure 4A ; Online Figure VIIA) . CXCR7 upregulation significantly attenuated ox-LDL-and HG-induced superoxide production in CXCR7-EPCs and almost completely blocked superoxide production after SDF-1 pretreatment ( Figure 4A ; Online Figure VIIA) . Using 3-nitrotyrosine as an oxidative damage marker, we obtained similar results ( Figure 4B ; Online Figure VIIB ): CXCR7 upregulation reduced 3-nitrotyrosine levels that were elevated by ox-LDL and HG exposure and CXCR7 completely blocked elevated 3-nitrotyrosine in the presence of SDF-1.
Upregulating CXCR7 Expression Activates Nrf2 via Akt/GSK-3β/Fyn Pathway in EPCs
Nrf2 plays a critical role in the cellular response to oxidative stress. 25, 26 Because increased CXCR7 expression decreased both ox-LDL-and HG-induced oxidative stress, we tested whether CXCR7 upregulation activate Nrf2 and its downstream target genes. There was no significant change in total Nrf2 protein and Nrf2 mRNA expression under any treatment condition in either Null-EPCs or CXCR7-EPCs (Figure 5A and 5B; Online Figure VIIIA) . However when treated with ox-LDL or HG, nuclear Nrf2 levels significantly declined in NullEPCs but not in CXCR7-EPCs. In fact, SDF-1 pretreatment significantly increased nuclear Nrf2 levels in CXCR7-EPCs compared with Null-EPCs ( Figure 5A ; Online Figure VIIIA) , which was also supported by studies of Nrf2 nuclear immunofluorescent localization in Null-EPCs and CXCR7-EPCs ( Figure 5C ). These results indicate that CXCR7 upregulation increased Nrf2 levels in the nucleus but did not increase total Nrf2 expression. Most importantly, we found that protein and mRNA expression of antioxidant Nrf2 target genes HO-1, NQO-1, and catalase were significantly higher in CXCR7-EPCs than in Null-EPCs in the presence of ox-LDL or HG, especially with SDF-1 pretreatment (Figure 5A and 5B; Online Figure VIIIA ). More importantly, CXCR7 upregulation-mediated Nrf2 nuclear translocation and downstream gene activation were also confirmed in early EPCs from db/db mice (Online Figure VIIIB) . These changes in Nrf2 target gene expression are fully consistent with the changes found in Nrf2 nuclear localization produced by CXCR7 upregulation (Figure 5A and 5C; Online Figure VIIIA and VIIIB) and suggest that SDF-1/ CXCR7 activates Nrf2 transcriptional function.
SDF-1/CXCR7 is thought to promote CD34 + hematopoietic stem/progenitor cell cycling and survival via Akt signaling, 27 and SDF-1/CXCR7 also regulates cell migration 28 by Akt signaling. Furthermore, the function of Nrf2 can be regulated by the Akt/GSK-3β/Fyn pathway in fibroblasts and PC12 cells by controlling Fyn-mediated export and degradation of nuclear Nrf2. 29, 30 We found that exposure of Null-EPCs and CXCR7-EPCs to ox-LDL or HG significantly decreased the phosphorylation of Akt and GSK-3β and increased the level of Fyn in the nucleus ( Figure 6A ; Online Figure IXA) . In CXCR7-EPCs, SDF-1 pretreatment prevented ox-LDL-and HG-induced decreases in Akt and GSK-3β phosphorylation and nuclear accumulation of Fyn ( Figure 6A ; Online Figure  IXA) . Furthermore, CXCR7 upregulation-mediated preservation of Akt/GSK-3β/Fyn pathway was also confirmed in early EPCs from db/db mice (Online Figure IXB) . More importantly, the ability of SDF-1 and CXCR7 to reverse the effects of ox-LDL and HG on Akt, GSK-3β, and Fyn were blocked by the specific pharmacological inhibitor of phosphatidylinositol 3-kinase/protein kinase B, Wortmannin ( Figure 6A ; Online 
Knockdown of Nrf2 Impairs the Protective Effects of CXCR7 on EPCs
To confirm the pivotal role of Nrf2 in SDF-1/CXCR7 protection, we performed knockdown of Nrf2 gene expression with Nrf2-shRNA (Online Figure XA) . The vector sh-Nrf2 2 had the best knockdown efficiency among the 3 Nrf2-shRNA (Online Figure XA) vectors tested, and this vector was used to knockdown Nrf2 in subsequent studies: Nonsense shRNA did not alter Nrf2 expression and was used as control vector. Knockdown of Nrf2 expression blocked most of the protective effects we had seen with SDF-1 and CXCR7 (Figures 2  through 6 ; Online Figures V through IX): In SDF-1-treated Figure 4 . Upregulating CXC chemokine receptor type 7 (CXCR7) expression attenuates the superoxide level and oxidative damage in endothelial progenitor cells (EPCs) induced by oxidized low-density lipoprotein (ox-LDL). A, Fluorescent Images and quantitation of superoxide levels in EPCs treated with or without ox-LDL (50 μg/mL) in the presence or absence of stromal cell-derived factor 1 (SDF-1) (100 ng/mL) for 6 h. Superoxide was determined with the fluorescent indicator dihydroethidium (DHE), and the fluorescent intensity of DHE was measured by a fluorescent microplate reader. B, Levels of the oxidative damage marker 3-nitroryrosine (3-NT) in EPCs treated with or without ox-LDL (50 μg/mL) in the presence or absence of SDF-1 (100 ng/mL) for 12 h was detected by Western blot. Three independent experiments were performed. Data shown in graphs represent the mean±SD. *P<0.05 vs respective control in Null-EPCs (EPCs transduced with control lentivirus) or CXCR7-EPCs; #P<0.05 vs Null-EPCs with the same treatment; &P<0.05 vs CXCR7-EPCs with ox-LDL treatment. Figure 5 . Upregulating CXC chemokine receptor type 7 (CXCR7) activates nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling in endothelial progenitor cells (EPCs). Null-EPCs (EPCs transduced with control lentivirus) or CXCR7-EPCs were exposed to oxidized low-density lipoprotein (ox-LDL; 0 or 50 μg/mL) in the presence or absence of stromal cell-derived factor 1 (SDF-1; 100 ng/mL) for 12 h. A, Protein levels of Nrf2 and its downstream target genes heme oxygenase-1 (HO-1), NAD(P)H dehydrogenase (quinone 1) (NQO-1), and catalase (CAT), and nuclear expression of Nrf2 (n-Nrf2) were detected by Western blot. B, The mRNA expression of Nrf2 and its downstream target genes HO-1, NQO-1, and CAT were determined by real-time polymerase chain reaction. C, Nrf2 nuclear translocation was determined in fixed cells by immunofluorescent staining. Three independent experiments were performed. Data shown in graphs represent the means±SD. *P<0.05 vs respective control in Null-EPCs or CXCR7-EPCs; #P<0.05 vs Null-EPC with the same treatment; &P<0.05 vs CXCR7-EPC with ox-LDL treatment. Figure XIIA and XIIB) . This result indicates that SDF-1/CXCR7 effects on Nrf2 are downstream of Akt/GSK/Fyn. Nrf2 knockdown tested in vivo by transplantation into db/db mice effectively eliminated the ability of elevated CXCR7 expression in CXCR7-EPCs to augment of EPC-mediated ischemic blood perfusion ( Figure 8A ) and angiogenesis ( Figure 8B ).
Discussion
Patients with type 1 or type 2 diabetes mellitus have decreased number and impaired angiogenic function of EPCs, which plays a causative role in the development and progression Figure 6 . Upregulating CXC chemokine receptor type 7 (CXCR7) activates nuclear factor (erythroid-derived 2)-like 2 (Nrf2) via protein kinase B (Akt)/glycogen synthase kinase (GSK)-3β/tyrosine kinase Fyn (Fyn) pathway. Null-EPCs (endothelial progenitor cells transduced with control lentivirus) or CXCR7-EPCs were pretreated with or without phosphatidylinositol 3-kinase inhibitor wortmannin for 30 min and then exposed to oxidized low-density lipoprotein (ox-LDL; 50 μg/mL) for 12 h in the presence or absence of stromal cell-derived factor 1 (SDF-1; 100 ng/mL). A, The phosphorylation of Akt and GSK-3β, and the nuclear translocation of Fyn (n-Fyn) were evaluated by Western blot. of virtually all diabetic complications. 31 Despite its critical importance, the mechanism for impaired EPC function in diabetes mellitus remains largely unknown. The present study provides 3 new lines of evidence implicating CXCR7 initiated pathways in diabetic EPC dysfunction: The first novel finding is the strong relationship between CXCR7 levels and diabetic EPC dysfunction: CXCR7 levels are decreased in diabetic EPCs, diabetic dysfunction is mimicked by CXCR7 knockdown, and EPC dysfunction is reversed by upregulation of CXCR7 levels. The second innovative finding is that the benefit of increased CXCR7 expression requires activation of Nrf2 antioxidant signaling. Our third novel finding is that the Akt/GSK-3β/Fyn pathway mediates CXCR7-induced Nrf2 activation in diabetic EPCs.
Emerging evidence indicates that CXCR7 is essential for regulation of multiple cellular functions. 32 Our previous studies demonstrated that CXCR7 plays a critical role in the regulation of adhesion and survival of EPCs from both rat bone marrow and human cord blood. 14, 15 In the present study, we demonstrate that diabetes mellitus significantly decreased EPC cellular and cell surface levels of CXCR7 but produces no similar change in CXCR4 levels ( Figure 1A  and 1B) . We addressed what factors in diabetes mellitus might cause downregulation of CXCR7 and dysfunction of EPCs. To test whether the decrease of CXCR7 expression in db/db EPCs could be caused by the dysmetabolic environment of diabetes mellitus, we exposed normal EPCs to elevated ox-LDL or HG to mimic dysmetabolic diabetic conditions, as previously reported. 22 The results show that ox-LDL and HG both dose dependently decrease CXCR7 but not CXCR4 levels (Online Figure IVA and IVC) and indicate that CXCR7 is a strong candidate for impairment Figure 6 Continued. The results were normalized to the control group of Null-EPCs. D, The apoptosis of EPCs was analyzed by flow cytometry using Annexin V/propidium iodide (PI) staining. E, The angiogenic function of EPCs was determined by tube formation assay; the tube length was normalized to the control group of Null-EPCs. F, The transendothelial migration abilities of EPCs was analyzed by transwell assay. Three independent experiments were performed for each study. Data shown in graphs represent the means±SD. *P<0.05 vs respective control in Null-EPCs or CXCR7-EPCs; #P<0.05 vs Null-EPC with the same treatment; &P<0.05 vs CXCR7-EPC with ox-LDL treatment in the presence of SDF-1.
of EPC function under dysmetabolic diabetic conditions. However, the exact molecular mechanism by which the diabetic stressors HG and ox-LDL, as well as nondiabetic stressors such as hypertension, 16 downregulate CXCR7 levels in EPCs remains unknown.
The most important, new finding of this study is that overexpression of CXCR7 rescued function of both diabetic EPCs and normal EPCs impaired by exposure to diabetic conditions in vitro or in vivo. Upregulation of CXCR7 levels restored angiogenic function of type 2 diabetic, db/db EPCs ( Figure 1D ), and protected normal EPCs treated with ox-LDL or HG from excess apoptosis and angiogenic dysfunction (Figure 3A and 3B; Online Figure VA and VB) . Moreover, upregulation of CXCR7 expression in normal or Figure 7 . Knockdown of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) attenuates the protective effects of CXC chemokine receptor type 7 (CXCR7) upregulation on endothelial progenitor cells (EPCs). CXCR7-EPCs or Null-EPCs (EPCs transduced with control lentivirus) were transfected with lentivirus vector encoding Nrf2 shRNA (CXCR7/sh-Nrf2-EPCs) or control shRNA (CXCR7/shCtrl-EPCs or Null/sh-Ctrl-EPCs). After shRNA transfection, the protective effects of SDF-1/CXCR7 on EPC survival, angiogenesis and transendothelial migration were evaluated as described in Figure 6 . A, Apoptosis was analyzed by flow cytometry. B, Angiogenic function was determined by tube formation assay. C, Transendothelial migration was analyzed by transwell assay. Three independent experiments were performed for each study. Data shown in graphs represent the means±SD. *P<0.05 vs respective control in Null/sh-Ctrl-EPCs, CXCR7/sh-Ctrl-EPCs or CXCR7/sh-Nrf2-EPCs; #P<0.05 vs Null/sh-Ctrl-EPC with the same treatment; &P<0.05 vs CXCR7/sh-Ctrl-EPC with the same treatment.
db/db EPCs promoted homing of EPCs to ischemic tissue, increased capillary density, and improved blood flow perfusion when EPCs were transplanted into a type 2 diabetic HLI model (Online Figure VI; Figure 2 ). It is well documented that elevated ox-LDL and hyperglycemic conditions can promote endothelial and smooth muscle dysfunction in Figure 8 . Knockdown of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) attenuates the beneficial effects of CXC chemokine receptor type 7 (CXCR7) upregulation on endothelial progenitor cell (EPC)-mediated angiogenesis in ischemic limb of db/db diabetic mice. The effects of Nrf2 knockdown on the beneficial effects of CXCR7 upregulation on EPC-mediated angiogenesis and blood perfusion were evaluated in the hindlimb ischemia (HLI) model in db/db diabetic mice as described in Figure 2 and Online Figure VI. established arterial and arteriolar vessels during diabetes mellitus. 33, 34 Thus, in addition to a profound impact on capillary density and neovascularization in diabetic animals reported here, a potential contribution of changes in EPC CXCR7 expression to basal myogenic tone development and vasodilatory capacity in small diameter arterioles and its impact on blood flow in diabetes mellitus warrants further investigation. Nonetheless, considering that CXCR7 overexpression reverses diabetic EPC dysfunction and improves EPC survival these results strongly support the concept that the decline in CXCR7 levels is a significant, causative factor in development of diabetic EPC dysfunction, and further indicate that CXCR7 is a new therapeutic target for improving the ischemia-reparative capacity of EPCs in patients with diabetes mellitus. Intriguingly, EPCs from hypertensive patients have also been shown to have reduced CXCR7 levels, which coincides with impaired function, 16 and like diabetic EPCs, their function can be rescued by overexpression of CXCR7. 16 The analogous findings for CXCR7 in diabetic and hypertensive EPCs emphasize the importance of CXCR7 in maintaining adequate EPC function.
The second innovative finding of this study is that the benefit of increased CXCR7 expression requires activation of Nrf2 antioxidant signaling. Accumulating evidence demonstrates that oxidative stress in type 2 diabetes mellitus contributes to endothelial cell and EPC dysfunction. 23, 24, 35 Intracellular ROS level is elevated in EPCs from diabetic mice or EPCs cultured under HG or high lipid conditions. 24, 35, 36 Methods that reduced intracellular ROS levels restore function of diabetic EPCs. 37, 38 In the present study, we found that the ROS level of EPCs cultured with ox-LDL or HG was increased. Upregulating CXCR7 expression, especially when combined with SDF-1 pretreatment, almost completely inhibited the increase in ROS level of EPCs exposed to ox-LDL or HG (Figure 4 ; Online Figure VII ). This indicates that upregulation of the SDF-1/CXCR7 axis improves EPC antioxidant capacity.
We had previously seen that Nrf2 is a critical redox sensor and one of the master regulators of the antioxidant response.
39 Nrf2 binds to regulatory antioxidant response elements and activates transcription of many antioxidant genes, such as HO-1, and NQO-1 that counteract ROS. 40 In this study, we demonstrate for the first time that upregulating CXCR7 markedly increased nuclear accumulation of Nrf2 and increases the expression of downstream antioxidant target genes (HO-1, NQO-1, and catalase; Figure 5 ; Online Figure VIII ). These results indicate that upregulating CXCR7 improves EPC antioxidant capacity by activating Nrf2 transcriptional function. The essential role Nrf2 plays in endothelial function has been widely appreciated. Florczyk et al 41 reported that lack of Nrf2 attenuated survival, proliferation, and angiogenic function of endothelial cells in vitro and in vivo, whereas angiogenic factors increased the nuclear localization of Nrf2 and the expression of its target genes HO1and NQO-1, which stimulated tube formation of endothelial cells. Furthermore, knockdown of Nrf2 inhibits angiogenesis of rat cardiac microvascular endothelial cells under hypoxic conditions. 42 Consistent with these findings in endothelial cells, our studies in EPCs revealed that lentivirus-mediated, shRNA knockdown of Nrf2 almost completely abrogated the ability of elevated CXCR7 levels to augment EPC survival and tube formation in vitro (Figure 7 ; Online Figure XI) and to enhance ischemic angiogenesis and blood perfusion in vivo (Figure 8 ). These findings prove that Nrf2 plays an essential role in the ability of CXCR7 upregulation to augment EPC function.
Our third important, new finding is that the Akt/GSK-3β/ Fyn pathway mediates the activation of Nrf2 produced by elevated CXCR7 in diabetic EPCs. The mechanism of Nrf2 activation has been widely investigated. 43, 44 In PC12 cells, it was found that puerarin triggers Akt activation, which in turn inhibits GSK-3β activation resulting in more Nrf2 nuclear translocation. Moreover, it was demonstrated that CXCR7 activates phosphatidylinositol 3-kinase/protein kinase B independently of CXCR4. 27, 28 In this study, diabetes mellitus, ox-LDL, and HG all reduced Akt phosphorylation in EPCs. Using in vitro studies, we showed that decreased Akt phosphorylation produced by ox-LDL or HG exposure could be prevented by SDF-1 if CXCR7 expression was elevated in EPCs ( Figure 6A ; Online Figure IXA and IXB), showing that augmentation of the SDF-1/CXCR7 axis activates Akt in EPCs. However, the direct linkage between the SDF-1/ CXCR7 axis and phosphorylation of Akt in EPCs remains a key unanswered question.
Several recent studies showing that the Akt/GSK-3β/Fyn pathway plays a pivotal role in regulation of Nrf2 nuclear export and degradation. 25, 29, 30, 45, 46 Based on those studies and Akt phosphorylation results, we hypothesized that SDF-1/ CXCR7 signaling activates Nrf2 via the Akt/GSK-3β/Fyn pathway. Consistent with this hypothesis, we found that stimulating the SDF-1/CXCR7 axis not only increased phosphorylation of Akt but also inhibited GSK-3β activity that decreased nuclear accumulation of Fyn ( Figure 6A ; Online Figure IXA and IXB). It is known that Fyn can phosphorylate Nrf2 tyrosines, promoting Nrf2 nuclear export and degradation. 45, 47 Importantly, we found that a phosphatidylinositol 3-kinase/protein kinase-specific inhibitor (wortmannin) almost completely abolished SDF-1/CXCR7 activation of Nrf2 and expression of its downstream genes (Figure 6B and 6C; Online Figure IXC ). This was accompanied by almost complete attenuation of the protective effects of SDF-1/CXCR7 activation on EPC survival and angiogenic function under ox-LDL and HG treatment conditions (Figure 6D and 6E; Online Figure IXD and IXE).
In conclusion, upregulation of signaling of the SDF-1/ CXCR7 axis improves EPC survival and function under diabetic conditions. This is predominantly because of increased Nrf2 activation, mediated in EPCs by increasing Akt and GSK-3β phosphorylation and inhibiting Fyn-mediated Nrf2 nuclear export and degradation. By preserving Nrf2 nuclear localization, Nrf2 function is enhanced and antioxidant gene expression is increased, protecting EPCs from diabetes mellitus, ox-LDL, and HG-induced oxidative damage as illustrated in Figure 8C .
